AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

4,037
Mkt Cap
$4.22B
Volume
2.25M
52W High
$13.49
52W Low
$6.69
PE Ratio
944.37
AMRX Fundamentals
Price
$13.17
Prev Close
$13.19
Open
$13.20
50D MA
$12.35
Beta
1.18
Avg. Volume
1.88M
EPS (Annual)
-$0.3783
P/B
-38.51
Rev/Employee
$336,621.33
Loading...
Loading...
News
all
press releases
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings Guidance
Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance. The company provided EPS guidance of 0.750-0.800 for the period...
MarketBeat·4d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High - Should You Buy?
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week High - Time to Buy...
MarketBeat·11d ago
News Placeholder
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
Zacks·11d ago
News Placeholder
Allspring Global Investments Holdings LLC Boosts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX
Allspring Global Investments Holdings LLC raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1,440.0% in the 3rd quarter, according to the company in its most recent...
MarketBeat·12d ago
News Placeholder
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat.com reports. One...
MarketBeat·24d ago
News Placeholder
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat reports. One...
MarketBeat·24d ago
News Placeholder
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX
Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 187.1% in the third quarter, according to the company in its most recent 13F filing...
MarketBeat·29d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week High - Still a Buy?
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by Barclays
Barclays upgraded Amneal Pharmaceuticals from an "overweight" rating to a "strong-buy" rating in a report on Monday...
MarketBeat·1mo ago
<
1
2
...
>

Latest AMRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.